Vetr lowered shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) from a hold rating to a sell rating in a report published on Monday morning. Vetr currently has $28.47 target price on the biopharmaceutical company’s stock.
Other equities analysts have also issued research reports about the company. Wedbush reissued a neutral rating and set a $24.00 target price on shares of Juno Therapeutics in a research note on Tuesday, June 6th. BidaskClub raised Juno Therapeutics from a hold rating to a buy rating in a research note on Tuesday, June 20th. Zacks Investment Research lowered Juno Therapeutics from a buy rating to a hold rating in a research note on Tuesday, May 2nd. BTIG Research lowered Juno Therapeutics from a neutral rating to a sell rating and increased their target price for the stock from $12.00 to $23.00 in a research note on Tuesday, June 6th. Finally, Morgan Stanley decreased their target price on Juno Therapeutics from $27.00 to $26.00 and set an equal weight rating on the stock in a research note on Monday, May 8th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of $30.86.
Shares of Juno Therapeutics (JUNO) traded down 2.6788% during trading on Monday, hitting $29.5759. The stock had a trading volume of 220,085 shares. The stock’s market cap is $3.08 billion. The company’s 50 day moving average price is $27.95 and its 200 day moving average price is $24.15. Juno Therapeutics has a 12 month low of $17.52 and a 12 month high of $35.04.
Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by $0.24. Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The firm had revenue of $21.30 million for the quarter, compared to analyst estimates of $15.59 million. During the same period in the previous year, the company posted ($0.64) EPS. Juno Therapeutics’s revenue was down 22.8% on a year-over-year basis. Equities research analysts expect that Juno Therapeutics will post ($3.05) earnings per share for the current fiscal year.
In other Juno Therapeutics news, major shareholder Douglas K. Bratton sold 8,000,000 shares of the stock in a transaction dated Thursday, July 13th. The stock was sold at an average price of $27.00, for a total value of $216,000,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Steve Harr sold 8,750 shares of the stock in a transaction dated Tuesday, June 27th. The shares were sold at an average price of $30.00, for a total value of $262,500.00. Following the completion of the sale, the chief financial officer now directly owns 736,189 shares in the company, valued at approximately $22,085,670. The disclosure for this sale can be found here. Insiders sold a total of 8,041,500 shares of company stock worth $217,230,360 in the last ninety days. 15.26% of the stock is owned by corporate insiders.
Large investors have recently bought and sold shares of the stock. State Board of Administration of Florida Retirement System raised its stake in Juno Therapeutics by 25.7% in the second quarter. State Board of Administration of Florida Retirement System now owns 84,214 shares of the biopharmaceutical company’s stock worth $2,517,000 after buying an additional 17,214 shares in the last quarter. Marshall Wace LLP bought a new stake in Juno Therapeutics during the second quarter worth about $1,071,000. Marshall Wace North America L.P. bought a new stake in Juno Therapeutics during the second quarter worth about $9,693,000. Jennison Associates LLC bought a new stake in Juno Therapeutics during the second quarter worth about $22,689,000. Finally, Bank of New York Mellon Corp raised its stake in Juno Therapeutics by 7.3% in the second quarter. Bank of New York Mellon Corp now owns 281,858 shares of the biopharmaceutical company’s stock worth $8,425,000 after buying an additional 19,057 shares in the last quarter. 64.60% of the stock is currently owned by institutional investors.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.